Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias

Anderson, Sheron; Blanski, Lori; Byrd, Randolph C.; Das, Gopal D.; Engler, Robert L.; Laddu, Atul R.; Lee, Robert; Rajfer, Sol I.; Schroeder, John S.; Steck, James; Sung, Ruey J.; Turlapaty, Prasad; Williams, David M.; Wilner, George D.; Zoble, Robert G.

doi:10.1016/0002-8703(86)90551-x

Cited by 76 publications

(17 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ablation procedures in patients with complex congenital heart disease are best performed in centers with advanced mapping techniques and expertise in congenital heart disease. 25,29,496 IIa B-NR 4. Surgical ablation of AT or atrial flutter can be effective in ACHD patients undergoing planned surgical repair.…”

Section: 449452454457458489-492mentioning

confidence: 99%

2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia

Page¹,

Joglar²,

Caldwell³

et al. 2016

Circulation

321

127

View full text Add to dashboard Cite

Section: 449452454457458489-492mentioning

confidence: 99%

2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia

Page¹,

Joglar²,

Caldwell³

et al. 2016

Circulation

321

127

View full text Add to dashboard Cite

“…Esmolol hydrochloride has been compared with placebo in a double-blind controlled study in SVT patients with heart rates of 120 beats/min or higher [19]. The improvement rate caused by esmolol hydrochloride was 66 %, based on a 20 % or greater heart rate reduction and a heart rate of less than 100 beats/min; the rate of recovery of sinus rhythm was 6 % [19].…”

Section: Discussionmentioning

confidence: 99%

The Effectiveness and Safety of Landiolol Hydrochloride, an Ultra-Short-Acting β1-Blocker, in Postoperative Patients with Supraventricular Tachyarrhythmias: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Taenaka

Kikawa

2013

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

BackgroundPersistent postoperative supraventricular tachyarrhythmias (SVTs) increase cardiac burden and aggravate cardiac hemodynamics. Therefore, for patients in unstable conditions after surgery, prompt and sustained control of heart rate is essential. The importance of β-adrenoceptor antagonists (β-blockers) in controlling such postoperative atrial fibrillation or atrial flutter has been established, and the usefulness of ultra-short-acting β1-blockers with high β1 selectivity has been suggested based on their safety and efficacy under such circumstances.ObjectivesOur objectives were to evaluate the effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-selective blocker, in the treatment of postoperative SVT in patients with a high risk of myocardial ischemia, or in patients after highly invasive surgery, in a multicenter, randomized, double-blind, placebo-controlled, group-comparative study.MethodsA total of 165 patients were randomly allocated to three groups and received LM or MH doses of landiolol hydrochloride or placebo. LM group: dose L (1-min loading dose at a rate of 0.03 mg/kg/min, followed by a 10-min infusion at 0.01 mg/kg/min) followed by dose M (1-min loading at a rate of 0.06 mg/kg/min, followed by a 10-min infusion at 0.02 mg/kg/min); MH group: dose M followed by dose H (1-min loading dose at a rate of 0.125 mg/kg/min, followed by a 10-min infusion at 0.04 mg/kg/min); placebo (PP) group: dose P (1-min loading dose at a rate of 0 mg/kg/min, followed by a 10-min infusion at 0 mg/kg/min) followed by another round of dose P. If the targeted heart-rate reduction was not obtained at the end of the first 10-min infusion, the higher dose was started. The primary endpoint was the percentage of patients who met the heart-rate reduction criteria (≥20 % reduction and <100 beats/min). The safety endpoint was the incidence of adverse events in each of the three groups.ResultsThe percentages of patients who met the heart-rate reduction criteria (≥20 % reduction and <100 beats/min) were 0.0, 60.4, and 42.0 % in the PP, LM, and MH groups, respectively. There were significant differences in the LM and MH groups relative to the PP group, but there was no significant difference between the LM and MH groups. No significant difference was observed in the incidence of adverse events among the three groups: 29.6 % in the PP group, 45.5 % in the LM group, and 43.1 % in the MH group.ConclusionLandiolol hydrochloride is effective and safe for patients with postoperative SVT.

show abstract

“…In patients with WPW syndrome, syncope should be taken seriously but is not necessarily associated with increased risk of SCD. 25 The rate of AVRT is faster when AVRT is induced during exercise, 26 yet the rate alone does not explain symptoms of near-syncope. Elderly patients with AVNRT are more prone to syncope or near-syncope than are younger patients, but the tachycardia rate is generally slower in the elderly.…”

Section: Page Et Al 2015 Acc/aha/hrs Svt Guideline: Executive Summarymentioning

confidence: 99%

2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary

Page¹,

Joglar²,

Caldwell³

et al. 2016

Circulation

View full text Add to dashboard Cite

Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias

Cited by 76 publications

References 5 publications

2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia

2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia

The Effectiveness and Safety of Landiolol Hydrochloride, an Ultra-Short-Acting β1-Blocker, in Postoperative Patients with Supraventricular Tachyarrhythmias: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary

Contact Info

Product

Resources

About